Results 121 to 130 of about 5,633 (170)
Some of the next articles are maybe not open access.
Effect of miltefosine on erythrocytes
Toxicology in Vitro, 2013Miltefosine, an alkylphosphocholine drug with antiparasite, antibacterial, antifungal and antineoplastic potency, is the only oral drug that can be used to treat visceral and cutaneous leishmaniasis. The effect of miltefosine is at least partially due to triggering of apoptosis.
Kousi Alzoubi +2 more
exaly +3 more sources
Miltefosine and cutaneous leishmaniasis
Current Opinion in Infectious Diseases, 2012Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed.Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran.
Paulo R L, Machado, Gerson, Penna
openaire +2 more sources
Miltefosine: issues to be addressed in the future
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to ...
J, Berman +9 more
openaire +2 more sources
Miltefosine to treat leishmaniasis
Expert Opinion on Pharmacotherapy, 2005Leishmaniasis exists in both visceral and cutaneous forms, and miltefosine is the first oral agent with demonstrable efficacy against both types of this disease. At a dose of approximately 2.5 mg/kg/day for 28 days, miltefosine is > 90% curative for visceral disease in India and cutaneous disease in Colombia.
openaire +2 more sources
Miltefosine: oral treatment of leishmaniasis
Expert Review of Anti-infective Therapy, 2006The well-known problems of classic treatment of the leishmaniases with pentavalent antimony (reduced efficacy), difficulties of administration and increasing frequency and severity of adverse events have stimulated the search for new drugs to treat these diseases. Other injectable, oral and topical drugs have not been consistently effective, especially
Jaime, Soto, Paula, Soto
openaire +2 more sources
Parasitology Research, 2014
Leishmania donovani is the causative agent of anthroponotic visceral leishmaniasis in the Indian subcontinent. Oral miltefosine therapy has recently replaced antimonials in endemic areas. However, the drug is at risk of emergence of resistance due to unrestricted use, and, already, there are indications towards decline in treatment efficacy.
Arpita, Kulshrestha +3 more
openaire +2 more sources
Leishmania donovani is the causative agent of anthroponotic visceral leishmaniasis in the Indian subcontinent. Oral miltefosine therapy has recently replaced antimonials in endemic areas. However, the drug is at risk of emergence of resistance due to unrestricted use, and, already, there are indications towards decline in treatment efficacy.
Arpita, Kulshrestha +3 more
openaire +2 more sources
Development of Miltefosine for the Leishmaniases
Mini-Reviews in Medicinal Chemistry, 2006The leishmaniases consist of visceral and cutaneous syndromes present in > 30 endemic regions of the world. Miltefosine (hexadecylephosphocholine) is the first oral agent that is effective and tolerated for both visceral and cutaneous disease in several endemic regions, and represents a major advance in the treatment of these diseases.
openaire +2 more sources